BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
30 juil. 2024 06h45 HE
|
BioNTech SE
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
29 juil. 2024 09h15 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Hummingbird Bioscience Announces Key Leadership Appointments
29 juil. 2024 08h00 HE
|
Hummingbird Bioscience
Hummingbird Bioscience Announces Key Leadership Appointments
• Kon Yew Kwek appointed Chief Medical Officer
• Lisa Ooi appointed Chief Operating Officer
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
25 juil. 2024 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
24 juil. 2024 08h50 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s...
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
23 juil. 2024 08h45 HE
|
INmune Bio, Inc.
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics BOCA RATON, Fla., July 23, 2024 ...
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22 juil. 2024 16h07 HE
|
TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
22 juil. 2024 08h20 HE
|
SciSparc Ltd
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- ...
The Alberta Cancer Foundation’s Enbridge Tour Alberta for Cancer Passes $100 Million Milestone in its 16th Year
20 juil. 2024 09h45 HE
|
Alberta Cancer Foundation
The 16th annual Enbridge Tour Alberta for Cancer in support of the Alberta Cancer Foundation marks $100M in total funds raised.
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
17 juil. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...